Press release
GSK2140944 (Gepotidacin) Drug Market Forecast and Analysis | GSK2140944 (Gepotidacin) for uncomplicated Urinary Tract Infection: Market Size Analysis and Competitive Landscape by DelveInsight
GSK2140944 (Gepotidacin) Drug Market Forecast and Analysis
The report also helps you to understand the GSK2140944 (Gepotidacin) clinical and commercial landscape along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, special designations, and commercial and development activities.
Download Sample Report to know the https://www.delveinsight.com/sample-request/gsk2140944-gepotidacin-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
GSK2140944 (Gepotidacin) Report Key Features and Coverage
The report presents a thorough description of GSK2140944 (Gepotidacin)'s characteristics and its use for uncomplicated Urinary Tract Infection, offering valuable insights into its drug's market potential. The report provides rich insights with respect to the competition in the market, as other emerging products that are in the advanced stage of pipeline development for uncomplicated Urinary Tract Infection are expected to give tough market competition to GSK2140944 (Gepotidacin). It is predicted that the launch of late-stage emerging therapies in the near future will significantly impact the uncomplicated Urinary Tract Infection market, and this report will help to understand how GSK2140944 (Gepotidacin) is going to compete against other drugs.
GSK2140944 (Gepotidacin) Drug Summary
GSK2140944, also known as Gepotidacin, is a novel antibiotic being developed by GSK for the treatment of uncomplicated urinary tract infections (uUTI). It belongs to a new class of antibiotics that was first discovered at GSK in 2007. Gepotidacin has a unique "dual targeting" mechanism of action (MOA) and is administered orally. Unlike currently approved antibiotics, Gepotidacin selectively interacts with two specific bacterial enzymes, DNA gyrase and topoisomerase IV (both type II topoisomerases), which play a crucial role in bacterial replication. This MOA enables Gepotidacin to effectively combat bacteria that have developed resistance to other antibiotics, including fluoroquinolones.
GSK has a long history of antibiotic research spanning over 45 years. Despite the reduction in the number of large pharmaceutical companies involved in this field, GSK maintains a dedicated research team focused on discovering new medicines to combat bacterial infections. Gepotidacin (GSK2140944) is the company's lead topoisomerase inhibitor, designed to address various indications, including uUTI. The development of this drug has been conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat Reduction Agency (DTRA).
Currently, Gepotidacin (GSK2140944) is in the Phase III stage of development. Prior to this, it successfully completed a Phase II clinical study. The drug is currently being evaluated in two Phase III clinical trials, which are randomized, multicenter, double-blind studies involving adolescent and adult females. These trials aim to compare the efficacy and safety of Gepotidacin to nitrofurantoin in the treatment of uUTI, specifically acute cystitis.
Stay ahead of the competition by leveraging key insights and evolving trends in the GSK2140944 (Gepotidacin) Market @ https://www.delveinsight.com/sample-request/gsk2140944-gepotidacin-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Why GSK2140944 (Gepotidacin) Market Report?
Leading GSK2140944 (Gepotidacin) for uncomplicated Urinary Tract Infection forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the GSK2140944 (Gepotidacin)
A thorough GSK2140944 (Gepotidacin) market forecast will help understand how the drug is competing with other emerging GSK2140944 (Gepotidacin)
Get an analysis of the GSK2140944 (Gepotidacin) clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
The report also provides future market assessments for GSK2140944 (Gepotidacin) market forecast analysis for uncomplicated Urinary Tract Infection in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in uncomplicated Urinary Tract Infection.
Download the sample report to learn more about the evolving market dynamics @ https://www.delveinsight.com/report-store/gsk2140944-gepotidacin-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related reports:
uncomplicated Urinary Tract Infection Market Report 2032
DelveInsight's "uncomplicated Urinary Tract Infection- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
uncomplicated Urinary Tract Infection Pipeline 2023
"uncomplicated Urinary Tract Infection Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Onycholysis market. A detailed picture of the Onycholysis pipeline landscape is provided, which includes the disease overview and Onycholysis treatment guidelines.
uncomplicated Urinary Tract Infection Epidemiology 2032
DelveInsight's 'uncomplicated Urinary Tract Infection - Epidemiology Forecast-2032' report delivers an in-depth understanding of the uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the uncomplicated Urinary Tract Infection trends in the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Leading Reports by DelveInsight:
Asthma Diagnostic Devices Market
Chronic Obstructive Pulmonary Disease Treatment Devices Market
Airway Management Devices Market
Cough Assist Devices Market
Pulse Oximeters Market
Hemodialysis Catheter Devices Market
Chronic Spontaneous Urticaria Market
Gender Dysphoria Market
Germany Healthcare Outlook
Biopsy Devices Pipeline Insight
Bacterial Conjunctivitis Market
Infliximab Biosimilar Insight
Eosinophilic Asthma Market
Cushing Syndrome Market
Functional Dyspepsia Market
Peripherally Inserted Central Catheters (PICC) Devices Market
Consulting Services:
DelveInsight's Healthcare Consulting Services offers a comprehensive and customized approach to address the diverse needs of clients in the healthcare sector. These services are specifically designed to tackle the most critical challenges faced by clients while also identifying and capitalizing on emerging opportunities.
By leveraging DelveInsight's deep industry knowledge, extensive market research capabilities, and advanced data analytics, healthcare consulting services provide clients with practical and data-driven solutions. The consultants collaborate closely with clients to gain a thorough understanding of their unique requirements and obstacles, enabling them to develop tailored strategies and solutions. DelveInsight's consulting expertise encompasses various aspects of the healthcare industry, including market access, commercial strategy, product development, and regulatory affairs.
Get in touch today to navigate the complexities of the life sciences industry and successfully achieve your business goals @ https://www.delveinsight.com/consulting
Contact Us:
Kritika Rehani
+91-9650213330
Email: info@delveinsight.com
https://www.delveinsight.com/
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release GSK2140944 (Gepotidacin) Drug Market Forecast and Analysis | GSK2140944 (Gepotidacin) for uncomplicated Urinary Tract Infection: Market Size Analysis and Competitive Landscape by DelveInsight here
News-ID: 3117712 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Gepotidacin
Uncomplicated Urinary Tract Infection Market Poised for Growth with Rising Aware …
Uncomplicated urinary tract infections (uUTIs), among the most common bacterial infections globally, predominantly affect otherwise healthy individuals, particularly women. Characterized by symptoms like dysuria, frequency, and urgency, uUTIs are generally confined to the lower urinary tract and are managed effectively with antibiotics. However, increasing antibiotic resistance, recurrent infections, and shifting treatment guidelines are reshaping the uncomplicated urinary tract infection market landscape.
DelveInsight's latest report, "Uncomplicated Urinary Tract Infection Market Insight, Epidemiology…
Hemorrhagic Cystitis Market Growth to Accelerate in Forecast Period (2023-2032), …
DelveInsight's "Hemorrhagic Cystitis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Hemorrhagic Cystitis, historical and forecasted epidemiology as well as the Hemorrhagic Cystitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Hemorrhagic Cystitis, offering comprehensive insights into the Hemorrhagic Cystitis revenue trends, prevalence, and treatment landscape. The…
Uncomplicated Urinary Tract Infection (UTI) Treatment Market Anticipated to Hit …
Urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, predominantly affecting women. The uncomplicated UTI treatment market has grown significantly due to the high prevalence of these infections and the widespread adoption of targeted antibiotic therapies. Uncomplicated UTIs typically affect the lower urinary tract and are primarily caused by bacteria such as Escherichia coli (E. coli). Treatment usually involves a short course of antibiotics, lasting between…
GSK2140944 (Gepotidacin) Market Size and Share Analysis Across 7MM and Competiti …
DelveInsight has released a comprehensive report titled "GSK2140944 (Gepotidacin) Market Forecast" offering a thorough examination and predictive insights into the GSK2140944 (Gepotidacin) market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of GSK2140944 (Gepotidacin) in the therapeutics landscape for uncomplicated Urinary…
Gonorrhoea Market Size was approximately USD XX Million in 2022, estimates Delve …
"The Gonorrhoea Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Gonorrhoea pipeline products will significantly revolutionize the Gonorrhoea market dynamics"
The Gonorrhoea market report provides current treatment practices, Gonorrhoea emerging drugs, market share of individual therapies, and current and forecasted 7MM a Gonorrhoea market size from 2019 to 2032. The report also covers current Gonorrhoea treatment…
Insights on the DNA Gyrase Subunit B (EC 5.99.1.3) Market to 2027 | Industry Sta …
The global DNA gyrase subunit B (EC 5.99.1.3) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). DNA gyrase is an essential bacterial enzyme that belongs to the topoisomerases class of enzymes that controls the topological transitions of DNA. Additionally, it catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. The major factor accelerating the growth of the market is the increasing prevalence of bacterial…
